Real‐world study of the use of azacitidine in myelodysplasia in Australia
Abstract Hypomethylating agents are the most widely used upfront therapy for patients with myelodysplastic syndrome (MDS) who are not suitable for hematopoietic stem cell transplantation. In Australia, azacitidine was, until recently, the only approved and subsidized treatment for patients with inte...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Wiley
2024-06-01
|
| Seri Bilgileri: | eJHaem |
| Konular: | |
| Online Erişim: | https://doi.org/10.1002/jha2.911 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|